With pharmaceutical regulation currently under review across Europe, Maarten Meulenbelt, Partner at Sidley Austin LLP, discusses some of the more controversial amendments under consideration.
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D